Point: Chemosensitivity assays have a role in the management of recurrent ovarian cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 1, 2011, Pages 115-120

  Schink, Julian C ^a   Copeland, Larry J ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Chemosensitivity assays; In vitro chemosensitivity testing; Personalized medicine; Recurrent ovarian cancer

Indexed keywords

CETUXIMAB; CISPLATIN; DOXORUBICIN; PLATINUM; TOPOTECAN; TRASTUZUMAB;

ASSAY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CHEMOSENSITIVITY; CLINICAL FEATURE; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; IN VITRO STUDY; LABORATORY TEST; LUMINESCENCE; OVARY CANCER; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; SALVAGE THERAPY;

EID: 78951474063     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0009     Document Type: Review

References (18)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Schilsky RL. Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J Clin Oncol 2009;27:3725-3730.
3. Salmon SE, Hamburger AW, Soehnlen B, et al. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 1978;298:1321-1327. (Pubitemid 8357629)
4. Von Hoff DD. He's not going to talk about in-vitro predictive assays again, is he? J Natl Cancer Inst 1990;82:96-101.
5. Loizzi V, Chan JK, Osann K, et al. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 2003;189:1301-1307. (Pubitemid 37542162)
6. Karam AK, Chiang JW, Fung E, et al. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Gynecol Oncol 2009;114:246-252.
7. Matsuo K, Eno ML, Im DD, et al. Clinical relevance of extent of extreme drug resistance inepithelial ovarian carcinoma. Gynecol Oncol 2010;116:61-65.
8. Cree IA, Kurbacher CM, Lamont A, et al. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 2007;18:1093-1101.
9. Salom EM, Penalver M, Homesley HD, et al. Can we increase response rate (RR) and overall survival (OS) by individualizing chemotherapy in ovarian cancer (OC): the role of a new chemotherapy (CT) induced apoptosis assay [abstract]. J Clin Oncol 2010;28(Suppl 1):Abstract 5112.
10. Gallion H, Christopherson WA, Coleman RL, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 2006;16:194-201.
11. Cannistra SA. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J Clin Oncol 2010;28:3101-3103.
12. Herzog TJ, Krivak TC, Fader AN, Coleman RL. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol 2010;203:68.e1-6.
13. Morgan J, Berry E, Lurain JR, et al. Sequential liposomal doxorubicin and topotecan salvage chemotherapy in platinum-resistant epithelial ovarian cancer: response to one drug dose does not predict response to the other. Presented at Western Association of Gynecologic Oncologists 38th Annual Meeting; June 24-27, 2009; Vancouver, BC.
14. Ness RB, Wisniewski SR, Eng H, Christopherson W. Cell viability assay for drug testing in ovarian cancer: in vitro kill versus clinical response. Anticancer Res 2002;22(2B):1145-1149.
15. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000;5:26-35.
16. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989;59:650-653. (Pubitemid 19111764)
17. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-393.
18. Rustin GJ, van der Burg ME. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 1.